Waldencast PLC（WALD）のニュースとイベントWALDWaldencast PLC

Middle East Violence Escalation Weighs on Markets, Tech Stocks Under Pressure

Macro narratives of re-escalation of violence in the Middle East, surging oil prices, and rising bond yields continued to weigh on sentiment, sending major averages down for the third consecutive session.   Once again, Energy and defensively oriented Utilities and Health care sectors softened the brunt of impact on the benchmark, though Tech, Basic Materials, Industrials, and Cyclicals paced the prevailing bearish bias.  In Tech, Software stocks joined the AI CapEx build out areas of the market - semiconductors, memory, hardware, and equipment - with outsized losses.  Applewas a notable counterweight however, gaining nearly 3% on the day.In the opening hour of the evening session, index futures are trading little changed - S&P e-minis are at 7,643 and Nasdaq 100 is just north of 29,100.  In commodities, WTI crude oil crossed the upside of $90 per barrel, boosted by more bellicose rhetoric from President Trump regarding his intentions to continue bombing Iran if IRGC retaliates against the latest round of US strikes.  Precious metals also remain under pressure, as rising dollar from growing expectations of higher short-term rates sent Gold below $4,370 per ounce.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER AFTER EARNINGS -GitLabup 15.9%Sportsman's Warehouseup 7.5%Dell Technologiesup 6.7%ALSO HIGHER -Waldencastup 9.6% after insider buyLineageup 1.8% after insider buyDOWN AFTER EARNINGS -MongoDBdown 12.9%Credo Technology Groupdown 9.2%Palo Alto Networksdown 1.8%

Waldencast Receives FDA Approval for Obagi saypha ChIQ Injectable Hyaluronic Acid Gel

Waldencast announced that the U.S. Food and Drug Administration has approved Obagi saypha ChIQ injectable hyaluronic acid gel, the latest addition to the Obagi injectable portfolio under the Obagi Medical brand. Developed by Croma-Pharma GmbH, the dermal filler is indicated for cheek augmentation and the correction of midface contour deficiencies in patients over the age of 21. "Obagi saypha ChIQ is a meaningful addition to our integrated aesthetic portfolio - giving practitioners and patients more ways to achieve end-to-end skin transformation with predictable, measurable outcomes, and bringing us closer to our vision of building the world's leading dermatological megabrand," said Michel Brousset, co-founder and CEO of Waldencast.

Canaccord Raises Waldencast Price Target to $3

Canaccord raised the firm's price target on Waldencast to $3 from $2 and keeps a Buy rating on the shares. The firm noted the company announced they have entered into an agreement to sell its Obagi skin care and aesthetics business to Bridgepoint. The transaction is valued up to $460M and comprises $366M in cash, a $10M fixed vendor note, a $20M adjustable vendor note, and up to $64M in earnout payments based on revenue milestones.